When Viagra Doesn't Work:
Novel ED Therapies Beyond PDE5 Inhibitors

PDE5 inhibitors — sildenafil (Viagra), tadalafil (Cialis), vardenafil (Levitra) — are effective for the majority of men with erectile dysfunction. But "majority" is not "all." Roughly 15–35% of men with ED either don't respond adequately to PDE5 inhibitors or can't take them due to cardiovascular medications. For these men, alternative pathways exist. They're less studied, less well-known, and all prescribed off-label — but they're real options, and at Revive, we prescribe all three.

This article is the honest overview. Not a sales pitch for any specific drug — a clinical map of what exists, what the evidence actually shows, and which patient profile each therapy fits.

Why PDE5 Inhibitors Don't Work for Everyone

PDE5 inhibitors work by increasing nitric oxide signaling in penile smooth muscle, which relaxes blood vessels and increases blood flow. The mechanism is vascular. If the cause of your ED is also vascular — atherosclerosis, diabetes-related microvascular disease, hypertension — PDE5 inhibitors are well-matched to the problem. But ED isn't always primarily vascular.

There are three categories of men for whom PDE5 inhibitors commonly fail:

• Non-responders: Men with severe vascular disease, post-prostatectomy neurological damage, or ED with a primarily psychological/desire-based component who simply don't respond to the vascular mechanism.
• Contraindicated patients: Men taking nitrate medications for heart conditions cannot safely use PDE5 inhibitors — the combination causes dangerous drops in blood pressure.
• Partial responders: Men who get some benefit from PDE5 inhibitors but whose response is inconsistent or insufficient — often indicating a mixed vascular/non-vascular etiology.

For these men, the three therapies below represent the current realistic options outside the PDE5 inhibitor class. None of them are FDA-approved for erectile dysfunction in men. All three are prescribed off-label in the US. That's the honest starting point.

The Three Novel ED Therapies: Side-by-Side

PT-141 (Bremelanotide)

PT-141 is the most studied of the three. It works in the brain — specifically on melanocortin receptors in the hypothalamus that regulate sexual desire and arousal. Unlike PDE5 inhibitors, it doesn't act on blood vessels at all. This makes it potentially useful for men whose ED has a neurological, psychological, or libido-based component. In clinical trials in PDE5 non-responders, PT-141 showed a ~33.5% response rate vs 8.5% for placebo. It's FDA-approved as Vyleesi for women (HSDD) and prescribed off-label for men. Full PT-141 guide →

Apomorphine

Apomorphine is a dopamine agonist taken as a sublingual (under-the-tongue) tablet. It's been approved for ED in the UK and EU (sold as Uprima) but is not FDA-approved for this use in the US, where it's prescribed off-label. Head-to-head against sildenafil, apomorphine showed about 55% response vs 74% for sildenafil — less effective, but via an entirely different mechanism that makes it viable for men who cannot safely use PDE5 inhibitors, particularly those on nitrate medications. Syncope (fainting) is a rare but serious risk that requires physician supervision. Full apomorphine guide →

Oxytocin

Oxytocin is the least-studied option. The evidence is primarily animal studies and small human pilot trials — it has not been through large-scale human RCTs for ED. Compounded intranasal oxytocin is hypothesized to enhance the arousal and intimacy dimensions of sexual activity. We prescribe it cautiously and only for appropriate patient profiles — typically men where the ED has a significant relational or psychological component, or as an adjunct alongside other treatments. Do not expect the same level of evidence as PT-141 or apomorphine. Full oxytocin guide →

For a full breakdown of all ED and PE medications — including PDE5 inhibitors, SSRIs for PE, and these novel therapies — see our complete ED & PE Medication Guide.